Our data clearly suggest that HNK targets c-Met-Ras-HO-1 tumorigenic pathways, and a combination therapy with HNK and other target-specific agent(s) can have promising benefits for the treatment of renal tumors, with particular importance to post-transplantation cancer. Here, HMOX1 is linked to cancer.